OncoHost combines life-science research and advanced machine-learning technology to develop personalized strategies to maximize the success of cancer therapy. By analyzing the patient’s proteins, the company aims to understand patients’ unique response to therapy and overcome resistance to therapy, one of the major obstacles in clinical oncology.
The company was founded in 2017 following more than a decade of academic research led by chief scientific adviser Professor Yuval Shaked, who also serves as the head of the Technion Integrated Cancer Center.